- Home
- VNET vs HRMY Comparison
VNET vs HRMY Comparison
Compare VNET & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNET
- HRMY
- Stock Information
- Founded
- VNET 1999
- HRMY 2017
- Country
- VNET China
- HRMY United States
- Employees
- VNET N/A
- HRMY N/A
- Industry
- VNET Computer Software: Programming Data Processing
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- VNET Technology
- HRMY Health Care
- Exchange
- VNET Nasdaq
- HRMY Nasdaq
- Market Cap
- VNET 2.1B
- HRMY 2.1B
- IPO Year
- VNET 2011
- HRMY 2020
- Fundamental
- Price
- VNET $9.49
- HRMY $32.48
- Analyst Decision
- VNET Strong Buy
- HRMY Strong Buy
- Analyst Count
- VNET 4
- HRMY 9
- Target Price
- VNET $11.20
- HRMY $55.33
- AVG Volume (30 Days)
- VNET 6.3M
- HRMY 620.2K
- Earning Date
- VNET 08-21-2025
- HRMY 10-28-2025
- Dividend Yield
- VNET N/A
- HRMY N/A
- EPS Growth
- VNET N/A
- HRMY 58.41
- EPS
- VNET N/A
- HRMY 3.10
- Revenue
- VNET $1,262,962,115.00
- HRMY $772,527,000.00
- Revenue This Year
- VNET $15.46
- HRMY $20.09
- Revenue Next Year
- VNET $20.35
- HRMY $16.74
- P/E Ratio
- VNET $419.61
- HRMY $10.78
- Revenue Growth
- VNET 17.85
- HRMY 17.74
- 52 Week Low
- VNET $2.68
- HRMY $26.47
- 52 Week High
- VNET $16.13
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- VNET 64.23
- HRMY 30.82
- Support Level
- VNET $7.68
- HRMY $32.87
- Resistance Level
- VNET $8.34
- HRMY $37.05
- Average True Range (ATR)
- VNET 0.58
- HRMY 1.15
- MACD
- VNET 0.13
- HRMY -0.59
- Stochastic Oscillator
- VNET 94.21
- HRMY 3.93
About VNET VNET Group Inc.
VNET started as AsiaCloud in 1999 and moved to the data center business with its first self-developed data center opening in 2010. The firm listed (as 21Vianet) on the Nasdaq in April 2011, subsequently changing its name to VNET Group in 2021. It originally focused on providing data center services such as colocation and cloud services to retail clients in China, but added hyperscale customers in 2019 and now counts large Chinese hyperscalers such as Alibaba Cloud, Tencent Cloud, and Huawei Cloud as customers. At the end of June 2025, it had 51,960 retail cabinets with the majority in Beijing, Shanghai, and the Greater Bay area. It also had 674 MW of wholesale capacity in service with a further 326 MW under construction and a further 792 MW held for future development.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.